|
|
|
Net profit up to June grows 16.2% and stands at € 0.91 million
(104,01 Kb)
|
|
|
|
|
|
In the first half of the year, Naturex’s revenues grow by 14.1% and net result increases by 28%, up to € 9.7 million
(187,20 Kb)
|
|
|
|
|
|
|
|
An excellent start to the year: Organic growth in sales of +17.5%, operating margin at 12.2% over sales and net income multiplied by 2
(135,66 Kb)
|
|
|
|
|
|
An excellent first quarter: Revenues increase 24%
(177,82 Kb)
|
|
|
|
|
|
The invested company increased its net profit by 118% at constant scope, and closed the year with a net result of 14.8 million euros
(156,53 Kb)
|
|
|
|
|
|
|
Xavier Adserà resignation as Director and Chairman of Natraceutical
(94,46 Kb)
|
|
|
|
|
|
|
Recovery of Forté Pharma sales in the second stand half: growth of 3% compared to 30% fall in the year to June, and appreciation of 46% stake in Naturex
(158,20 Kb)
|
|
|
|
|
|
Replacement of a director of the Natraceutical Board
(73,35 Kb)
|
|
|
|
|
|
2010 results posting date
(66,27 Kb)
|
|
|
|
|
|
|
Objectives exceeded by far: +21.6% organic growth in 2010 sales
(692,40 Kb)
|
|
|
|
|
|
The company informs of its exit from the Board of Directors of Naturex and the new consideration of the stake in the French multinational as a financial investment.
(72,04 Kb)
|
|
|
|
|
|
|
First quarter of sales recovery in Forté Pharma: +6.5% increase in the third stand quarter, after a fall of 26% in the year to June
(155,97 Kb)
|
|
|
|
|
|
|
September acumulates a record net profit of 10.8 million euros.
(139,18 Kb)
|
|
|
|
|
|
|
Growth continues to confirm: Sales increased 30% in 3Q and 21% up to September.
(167,75 Kb)
|
|
|
|
|
|
|
Natraceutical signs a memorandum of understanding for the development of Forté Pharma in Brazil and the listing of Natraceutical in that stock market.
(107,67 Kb)
|
|
|
|
|
|
|
The company is targeting sales growth of 10-15% at constant scope and in constant currencis, versus privious 5-10%.
(129,59 Kb)
|
|
|
|
|
|
|
Recovery of the net profit to 0.78 million Euro compared with -2.07 million Euro in June 2009
(329,96 Kb)
|
|
|
|
|
|
Net profit for the first half of 2010 amounts to 7.6 million Euro, up 45.7%
(108,22 Kb)
|
|
|
|
|
|
Good pace of integration of Natraceutical’s Ingredients Division: 8.3% growth in sales for the second quarter and 17.7% in the total semester
(138,59 Kb)
|
|
|
|
|
|
|
During the first quarter of 2010, Natraceutical increased its net proft by 70%, reaching a figure of 1.77 million euro.
(909,67 Kb)
|
|
|
|
|
|
Natraceutical closes 2009 with a negative result of € 43.99 M, attributable to the accounting impact of the Naturex operation
(610,44 Kb)
|
|
|
|
|
|
Naturex, the French multinational corporation in which Natraceutical holds a 35% stake, discloses their 2009 turnover.
(191,96 Kb)
|
|
|
|
|
|
The Spanish Ministry of Science and Innovation has approved an R+D project by Natraceutical Group within the CENIT Programme.
(935,83 Kb)
|
|
|
|
|
|
Natraceutical Group issue their third quarter results.
(608,27 Kb)
|
|
|
|
|
|
Natraceutical signs a strategic alliance with BioNike for the penetration of Forté Pharma in Italy and the entry into the cosmeceutic market.
(219,68 Kb)
|
|
|
|
|
|
|
Natraceutical Group has started negotiations with the main creditor entities to refinance the financial debt and carry out its restructuring process.
(122,64 Kb)
|
|
|
|
|
|
|
Document presented on October 15th 2009 by the chairmans of Natraceutical and Naturex, at the Madrid Stock Exchange
(5.117,58 Kb)
|
|
|
|
|
|
Forté Pharma obtains the authorisation to develop and market medicines in Europe.
(219,41 Kb)
|
|
|
|
|
|
Natraceutical Group issue their 1st half results.
(478,92 Kb)
|
|
|
|
|
|
Natraceutical Group and publicly-traded French company Naturex reach an agreement to create a world leading company of natural ingredients.
(72,01 Kb)
|
|
|
|
|
|
Natraceutical Group issue their 1st quarter results.
(310,21 Kb)
|
|
|
|
|
|
Natraceutical Group appoints Julien Laporte General Manager of the Food Supplement Division.
(237,58 Kb)
|
|
|
|
|
|
|
Natraceutical Group closes 2008 with 5.3% growth in sales ans 13.6% in EBITDA in a year of streamlining of their industrial structures.
(248,57 Kb)
|
|
|
|
|
|
Natraceutical Group further improves its performance ratios with 7.5% EBITDA growth and 17% recurrent earnings.
(96,59 Kb)
|
|
|
|
|
|
|
UK study contributes new evidence on the benefits of pectin agains cancer, of which Natraceutical is the sixth world-wide producer.
(192,47 Kb)
|
|
|
|
|
|
Grupo Kiluva increases its stake in Natraceutical up to 7,51%.
(185,43 Kb)
|
|
|
|
|
|
Natraceutical Group registers the patent for a new naturally-sourced bioactive compound featuring antihypertensive and anti-degenerative properties.
(78,76 Kb)
|
|
|
|
|
|
Natraceutical Group creates a personalized online coaching service on health, wellness and beauty.
(245,65 Kb)
|
|
|
|
|
|
Natraceutical Group's net profit rose 13.6% during the first half of 2008.
(305,54 Kb)
|
|
|
|
|
|
Natraceutical Group and the Swiss company Bühler have united their technology and commercial capacity in a unique joint development in their sector.
(103,77 Kb)
|
|
|
|
|
|
Natraceutical Group increases EBITDA by 25% and net profit by 40% in the first quarter of 2008.
(103,69 Kb)
|
|
|
|
|
|
|
Natraceutical expands the body of directors to reinforce the upcoming plans of expansion.
(99,95 Kb)
|
|
|
|
|
|
2007 marks the consolidation of Natraceutical Group fuelled by strong organic growth and recent acquisitions.
(143,48 Kb)
|
|
|
